Jefferson Health Plans

# *PRIOR AUTHORIZATION REQUEST FORM*

Individual and Family Plans

## Rinvoq

**Fax back to: (833) 605-4407**

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

| **Patient Name:** | **Prescriber Name:** |
|---|---|
| Member Number: | Fax: Phone: |
| Date of Birth: | Office Contact: |
| Line of Business: □ Exchange - PA | NPI: State Lic ID: |
| Address: | Address: |
| City, State ZIP: | City, State ZIP: |
| Primary Phone: | **Specialty/facility name (if applicable):** |

☐ REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

| | |
|---|---|
| Drug Name: | |
| Strength: | |
| Directions / SIG: | |

**Please attach any pertinent medical history including labs and information for this member that may support approval.**

**Please answer the following questions and sign.**

Q1. Will the patient be taking this drug concomitantly with another biologic Disease Modifying Anti-Rheumatic Drug (DMARD), a targeted synthetic DMARD, JAK inhibitors, or with potent immunosuppressants such as azathioprine and cyclosporine?

☐ Yes ☐ No

Q2. Is the patient within the appropriate age group listed in the FDA labeling for the indication which this drug is being prescribed?

☐ Yes ☐ No

Q3. Is this a reauthorization request? If YES, go to 4. If NO, go to 5.

☐ Yes ☐ No

Q4. Is there confirmation of continued positive clinical response since starting Rinvoq / Rinvoq LQ?

☐ Yes ☐ No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Jefferson Health Plans

***PRIOR AUTHORIZATION REQUEST FORM***
Individual and Family Plans

## Rinvoq

**Fax back to: (833) 605-4407**
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

| **Patient Name:** | **Prescriber Name:** |
|---|---|

Q5. Is the drug prescribed by or in consultation with an appropriate specialist per diagnosis: gastroenterologist, rheumatologist, or dermatologist?

☐ Yes ☐ No

Q6. Are chart notes attached documenting a diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), active ulcerative colitis (UC), active ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), active Crohn's disease (CD), or polyarticular juvenile idiopathic arthritis (pJIA)? If YES, go to 7. If NO go to 8.

☐ Yes ☐ No

Q7. Is there a documentation of inadequate response, intolerance, or contraindication to at least one TNF blocker? If YES, go to 11.

☐ Yes ☐ No

Q8. Are chart notes attached documenting a diagnosis of atopic dermatitis? If YES, go to 9. If NO, go to 10.

☐ Yes ☐ No

Q9. Is there a documentation of inadequate response, intolerance, or contraindication to at least one other systemic drug (including biologics) used to treat refractory, moderate to severe atopic dermatitis? (Please attach documentation). If YES, go to 11.

☐ Yes ☐ No

Q10. Are chart notes attached documenting a diagnosis of giant cell arteritis (GCA)?

☐ Yes ☐ No

Q11. Is there documentation of inadequate response, intolerance, or contraindication to at least one systemic corticosteroid?

☐ Yes ☐ No

Q12. Additional Information:

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Jefferson Health Plans

***PRIOR AUTHORIZATION REQUEST FORM***
Individual and Family Plans

# Rinvoq

**Fax back to: (833) 605-4407**
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

| **Patient Name:** | **Prescriber Name:** |
|---|---|
| | |

_____ _____

Prescriber Signature Date

*v2025*

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document